FUNDAMENTALS |
MarketCap: |
4.34 mill
|
EPS: |
-0.820
|
P/E: |
-0.0400
|
Earnings Date: |
Mar 24, 2024 |
SharesOutstanding: |
132.64 mill
|
Avg Daily Volume: |
9.98 mill
|
RATING
2024-04-05 |
B-
|
Sell
|
RATINGS |
Rating CashFlow: |
Strong Sell
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Neutral
|
|
DE: |
Strong Sell
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0400 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-0.01x
|
Company: PE -0.0400 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ -0.0251 - 0.0549
( +/- 268.46%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-01-31 | Moch Kenneth I | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Wills Stephen T | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Tomasello Shawn | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Adams Julian | Buy | 200 000 | Ordinary Shares |
2024-01-31 | Simantov Ronit | Buy | 480 319 | Ordinary Shares |
INSIDER POWER |
94.76
|
Last
90 transactions |
Buy:
8 073 627 | Sell:
418 674 |
Forecast:
16:00 - $0.0349
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0349
Forecast 2: 16:00 - $0.0349
Forecast 3: 16:00 - $0.0349
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0327 (0.00% )
|
Volume |
23.04 mill
|
Avg. Vol. |
9.98 mill
|
% of Avg. Vol |
230.77 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For GMDA
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | sell | $0.371 | N/A | Active |
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.